BRIEF—Novartis presents positive data for Gilenya in pediatric MS

Switzerland’s Novartis has announced positive data from the Phase III PARADIGMS study into Gilenya (fingolimod) versus current standard of care as a treatment for multiple sclerosis (MS).

The trial, which enrolled children and adolescents aged 10 to 17, showed treatment with Gilenya resulted in an 82% reduction in the rate of relapses compared to interferon beta-1a1.

The company says the safety profile of Gilenya was consistent with that seen in previous clinical trials, with more adverse events reported in the interferon group.

Gilenya is not currently approved for the treatment of pediatric MS. Novartis is working on submission with health authorities worldwide.